Soria-Chacartegui, P.; Villapalos-GarcÃa, G.; López-Fernández, L.A.; Navares-Gómez, M.; MejÃa-Abril, G.; Abad-Santos, F.; Zubiaur, P.
Clinical Relevance of Novel Polymorphisms in the Dihydropyrimidine Dehydrogenase (DPYD) Gene in Patients with Severe Fluoropyrimidine Toxicity: A Spanish Case-Control Study. Pharmaceutics 2021, 13, 2036.
https://doi.org/10.3390/pharmaceutics13122036
AMA Style
Soria-Chacartegui P, Villapalos-GarcÃa G, López-Fernández LA, Navares-Gómez M, MejÃa-Abril G, Abad-Santos F, Zubiaur P.
Clinical Relevance of Novel Polymorphisms in the Dihydropyrimidine Dehydrogenase (DPYD) Gene in Patients with Severe Fluoropyrimidine Toxicity: A Spanish Case-Control Study. Pharmaceutics. 2021; 13(12):2036.
https://doi.org/10.3390/pharmaceutics13122036
Chicago/Turabian Style
Soria-Chacartegui, Paula, Gonzalo Villapalos-GarcÃa, Luis A. López-Fernández, Marcos Navares-Gómez, Gina MejÃa-Abril, Francisco Abad-Santos, and Pablo Zubiaur.
2021. "Clinical Relevance of Novel Polymorphisms in the Dihydropyrimidine Dehydrogenase (DPYD) Gene in Patients with Severe Fluoropyrimidine Toxicity: A Spanish Case-Control Study" Pharmaceutics 13, no. 12: 2036.
https://doi.org/10.3390/pharmaceutics13122036
APA Style
Soria-Chacartegui, P., Villapalos-GarcÃa, G., López-Fernández, L. A., Navares-Gómez, M., MejÃa-Abril, G., Abad-Santos, F., & Zubiaur, P.
(2021). Clinical Relevance of Novel Polymorphisms in the Dihydropyrimidine Dehydrogenase (DPYD) Gene in Patients with Severe Fluoropyrimidine Toxicity: A Spanish Case-Control Study. Pharmaceutics, 13(12), 2036.
https://doi.org/10.3390/pharmaceutics13122036